Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
0% from low
No one on the platform currently holds DMKPQ.
No tracked institution reports a position in DMKPQ as of their last filing.
No one on the platform has traded DMKPQ yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $29M | +72.2% | $-0.17 | $-0.17–$-0.17 | — | 1 |
| 2027 | $50M | +69.9% | $0.18 | $0.18–$0.18 | 0.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2022-12-31 | $-1.40 | $-1.55 | -10.9% |
| 2022-09-29 | $-2.10 | $-2.05 | +2.2% |
| 2022-03-30 | $-2.45 | $-4.84 | -97.7% |
| +0.00% |
| $107 |
| — |
| EFTReFFECTOR Therapeutics, Inc. | $0.00 | +0.00% | $941 | — |
| IMVIFIMV Inc. | $0.00 | +0.00% | $23423 | — |
Source: Financial Modeling Prep · peers by sector/industry
$DMKPQ Please, correct me if I am wrong. I deepened my research with the help of AI and checking the docs and realized that, very likely, is really over for us. Seems we should have initiated a DERIVATIVE LAWSUIT so we could have had a voice (a presence) in the liquidation case and so, not removed by the liquidation trustee and the judge. So, even if the judge will require Catalent and USworldmeds to pay the damages, these will go to creditors only and if the damages claimed will be humongous will be simbolically only and money will remain to those companies. What a fraud, what a disgusting system! I hope everyone in charge will get their karma. (FU) $TBLT Another chit case
View on StockTwits ↗$DMKPQ If it's game over and we were wiped out, why our offline shares still not removed by brokers?
View on StockTwits ↗$DMKPQ This is what I thought then and asked AI. Thanks AI: DMK Pharmaceuticals (formerly Adamis Pharmaceuticals) faced an operational and legal deadlock that made a quick pivot nearly impossible. They couldn't simply "walk away" earlier due to exclusive contractual obligations, lack of liquidity, and the technical complexity of pharmaceutical manufacturing. Here are the main reasons why they waited until the Chapter 11 filing to take legal action: 1. Contractual Constraints and "Lock-in" Exclusivity Agreements: DMK had exclusive commercialization deals with US WorldMeds (USWM) for key products like the Zimhi nasal spray. Unilaterally breaking these contracts would have exposed the company to massive penalties and immediate legal battles they couldn't afford. Long-term Contracts with Catalent: The supply agreement with Catalent for the Symjepi product dated back to 2015 and had been automatically extended, tying DMK to a single manufacturer for years.
View on StockTwits ↗$DMKPQ Transcript regarding Hearing Held 1/20/2026 RE: Rule 16 Conference. Remote electronic access to the transcript is restricted until 5/4/2026. The transcript may be viewed at the Bankruptcy Court Clerk's Office. For information about how to obtain a transcript, call the Clerk's Office or Contact the Court Reporter/Transcriber, Reliable, at Telephone number 302-654-8080. Filed by Reliable Companies . Notice of Intent to Request Redaction Deadline Due By 2/9/2026. https://cases.creditorinfo.com/dmk/documents/docket
View on StockTwits ↗$DMKPQ Unbelievable, after all these days, nothing. 🤦🏻
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.